Clinical Trial

Phase IIa Trial of Oral SSS17 for Post-Arthroplasty Anemia

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated June 11, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
To assess the safety, tolerability, efficacy, and pharmacokinetic/pharmacodynamic (PK/PD) characteristics of orally administered SSS17 capsules in patients with postoperative anemia following elective total hip or knee arthroplasty.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-05.
Trial Details
NCT Number NCT07007936
Lead Sponsor Shenyang Sunshine Pharmaceutical Co., LTD.
Conditions Postoperative Anemia, Arthroplasty, Replacement, Hip, Arthroplasty, Replacement, Knee
Enrollment 90 participants
Start Date 2025-07
Primary Completion 2026-04 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-06-11